These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
483 related articles for article (PubMed ID: 11939870)
1. Placebo response in studies of major depression: variable, substantial, and growing. Walsh BT; Seidman SN; Sysko R; Gould M JAMA; 2002 Apr; 287(14):1840-7. PubMed ID: 11939870 [TBL] [Abstract][Full Text] [Related]
2. Placebo control groups in trials of major depressive disorder among older patients. Walsh BT; Sysko R J Clin Psychopharmacol; 2005 Aug; 25(4 Suppl 1):S29-33. PubMed ID: 16027558 [TBL] [Abstract][Full Text] [Related]
3. Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis. Iovieno N; Papakostas GI J Clin Psychiatry; 2012 Oct; 73(10):1300-6. PubMed ID: 23140647 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials. Tedeschini E; Levkovitz Y; Iovieno N; Ameral VE; Nelson JC; Papakostas GI J Clin Psychiatry; 2011 Dec; 72(12):1660-8. PubMed ID: 22244025 [TBL] [Abstract][Full Text] [Related]
5. Demographic variables, design characteristics, and effect sizes of randomized, placebo-controlled, monotherapy trials of major depressive disorder and bipolar depression. Papakostas GI; Martinson MA; Fava M; Iovieno N J Clin Psychiatry; 2016 May; 77(5):e619-24. PubMed ID: 27249092 [TBL] [Abstract][Full Text] [Related]
6. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses. Sinyor M; Levitt AJ; Cheung AH; Schaffer A; Kiss A; Dowlati Y; Lanctôt KL J Clin Psychiatry; 2010 Mar; 71(3):270-9. PubMed ID: 20122371 [TBL] [Abstract][Full Text] [Related]
7. Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder? Iovieno N; Papakostas GI J Clin Psychiatry; 2012 May; 73(5):676-83. PubMed ID: 22569112 [TBL] [Abstract][Full Text] [Related]
8. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. Khin NA; Chen YF; Yang Y; Yang P; Laughren TP J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123 [TBL] [Abstract][Full Text] [Related]
9. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. Papakostas GI; Perlis RH; Scalia MJ; Petersen TJ; Fava M J Clin Psychopharmacol; 2006 Feb; 26(1):56-60. PubMed ID: 16415707 [TBL] [Abstract][Full Text] [Related]
10. Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants. Freeman MP; Mischoulon D; Tedeschini E; Goodness T; Cohen LS; Fava M; Papakostas GI J Clin Psychiatry; 2010 Jun; 71(6):682-8. PubMed ID: 20573327 [TBL] [Abstract][Full Text] [Related]
11. The Psychiatric Inclusion and Exclusion Criteria in Placebo-Controlled Monotherapy Trials of Bipolar Depression: An Analysis of Studies of the Past 20 Years. Zimmerman M; Holst CG; Clark HL; Multach M; Walsh E; Rosenstein LK; Gazarian D CNS Drugs; 2016 Dec; 30(12):1209-1218. PubMed ID: 27541608 [TBL] [Abstract][Full Text] [Related]
12. Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach. Tedeschini E; Fava M; Papakostas GI J Clin Psychiatry; 2011 Jan; 72(1):98-113. PubMed ID: 21208576 [TBL] [Abstract][Full Text] [Related]
13. Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials. Iovieno N; Tedeschini E; Bentley KH; Evins AE; Papakostas GI J Clin Psychiatry; 2011 Aug; 72(8):1144-51. PubMed ID: 21536001 [TBL] [Abstract][Full Text] [Related]
14. Less is more in antidepressant clinical trials: a meta-analysis of the effect of visit frequency on treatment response and dropout. Rutherford BR; Cooper TM; Persaud A; Brown PJ; Sneed JR; Roose SP J Clin Psychiatry; 2013 Jul; 74(7):703-15. PubMed ID: 23945448 [TBL] [Abstract][Full Text] [Related]
15. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901 [TBL] [Abstract][Full Text] [Related]
16. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Papakostas GI; Fava M Eur Neuropsychopharmacol; 2009 Jan; 19(1):34-40. PubMed ID: 18823760 [TBL] [Abstract][Full Text] [Related]
17. Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents. Cox GR; Callahan P; Churchill R; Hunot V; Merry SN; Parker AG; Hetrick SE Cochrane Database Syst Rev; 2012 Nov; 11():CD008324. PubMed ID: 23152255 [TBL] [Abstract][Full Text] [Related]